POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
P/E ratio for POINT Biopharma Global Inc. (PNT)
P/E ratio as of 2022: 7.12
According to POINT Biopharma Global Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 7.12. At the end of 2021 the company had a P/E ratio of -9.01.
P/E ratio history for POINT Biopharma Global Inc. from 2019 to 2022
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2022 | 7.12 |
| 2021 | -9.01 |
| 2020 | -40.47 |
| 2019 | 0.00 |